# NewAmsterdam Pharma (NAMS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/NAMS
## Company Profile
- Ticker: NAMS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Netherlands
- Tags: Cardio-Metabolic
## Stock Data
- Close: 27.83 USD
- Market cap: 3707025174.09 USD
- Last updated: 2026-08-12
## Business Overview
### Oral Lipid-Lowering Therapies
NewAmsterdam Pharma develops oral therapies for cardiovascular disease. Its lead program targets CETP to produce substantial reductions in LDL cholesterol.
### Obicetrapib
Obicetrapib is an oral CETP inhibitor being developed for patients who need additional LDL reduction despite existing lipid-lowering therapy.
### Fixed-Dose Combination
NewAmsterdam is also developing obicetrapib as a fixed-dose combination with ezetimibe, pairing two oral mechanisms in a single tablet.
### Phase 3 Program
The BROADWAY, BROOKLYN, TANDEM, PREVAIL, REMBRANDT and RUBENS studies evaluate lipid lowering and cardiovascular outcomes across broad and genetically defined patient populations.
## Why The Stock Is Moving

As of Aug 12, 2026, NAMS closed up 0.76% at $27.83. No new same-company headline was identified in the current news window.

## Future Catalysts

- Regulatory decisions in the European Union, United Kingdom and Switzerland in the second half of 2026.
- Topline Phase 3 RUBENS data by year-end 2026.
- Potential launches by Menarini in Germany and the United Kingdom in the fourth quarter of 2026, subject to approval.

## Recent News
- 2026-08-06 20:01 EST — [NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-39377bb8) — Source: NewAmsterdam Pharma
- 2026-08-05 11:00 EST — [NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-provides-corporate-update-and-reports-second-quarter-financi-71d32549) — Source: NewAmsterdam Pharma
- 2026-07-29 12:00 EST — [NewAmsterdam Pharma to Host Investor Day on August 5, 2026](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-to-host-investor-day-on-august-5-2026-00cdef02) — Source: NewAmsterdam Pharma
- 2026-07-24 12:00 EST — [NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-and-menarini-group-receive-positive-chmp-opinion-recommendin-6e39bfc3) — Source: NewAmsterdam Pharma
- 2026-07-01 12:00 EST — [NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-announces-upcoming-presentations-at-the-alzheimer-s-associat-5f8e7eb9) — Source: NewAmsterdam Pharma